Clover Health Investments Maintains Hold Rating from Leerink Partners, Price Target at $2.50

Leerink Partners has reaffirmed its Hold rating on Clover Health Investments (CLOV) with a price target of $2.50. The report was released by Whit Mayo, who covers the Healthcare sector. CLOV's market cap is currently $1.15B and has a P/E ratio of -25.43. Clover Health Investments also received a Hold from UBS's Jonathan Yong and a Buy rating from Canaccord Genuity.

Clover Health Investments (CLOV) has been the subject of varied analyst opinions in recent weeks, with some firms maintaining their Hold ratings while others have shifted their stance. Leerink Partners has reaffirmed its Hold rating on CLOV with a price target of $2.50, a significant downgrade from previous targets. Meanwhile, UBS's Jonathan Yong has also maintained a Hold rating, while Canaccord Genuity has given the stock a Buy rating.

CLOV's market cap currently stands at $1.15 billion, with a P/E ratio of -25.43. The stock has seen significant volatility, with a 4.1% decline over the last month [2]. Despite the recent decline, analysts remain optimistic about the company's long-term prospects, with Matt Hewitt from Craig-Hallum maintaining a Buy rating with a price target of $4.13, representing a 45.2% upside from the current share price [2].

The upcoming earnings report, scheduled for Tuesday after market close, is expected to provide more clarity on the company's financial health. CLOV is anticipated to report adjusted earnings of $0.03 per share, in line with the Zacks Consensus Estimate, and revenue of $469.5 million for the current quarter, a 31.8% year-over-year increase [4].

However, the stock has faced challenges in recent months, with a 27.33% loss since July 28, 2025, and a 4-day losing streak ending on August 8, 2025 [1]. The stock has also been oversold on the RSI14 indicator, which can indicate a potential reversal but also increases the general risk [1].

Investors should closely monitor the earnings report and analyst recommendations to make informed decisions about CLOV. The upcoming earnings announcements will provide more insight into the company's financial health and could influence its stock price.

References:
[1] https://stockinvest.us/stock/CLOV
[2] https://www.ainvest.com/news/clover-health-mimedx-group-receive-bullish-analyst-sentiments-2508/
[3] https://finance.yahoo.com/news/clover-health-clov-reports-earnings-031925571.html
[4] https://www.nasdaq.com/articles/clover-health-investments-corp-clov-q2-earnings-meet-estimates